Wilsey Asset Management Inc. Invests $32.44 Million in Zimmer Biomet Holdings, Inc. $ZBH

Key Points

• Wilsey Asset Management acquired a new position of 360,753 shares in Zimmer Biomet, valued at approximately $32.44 million, which represents 5.0% of Wilsey’s portfolio and about 0.18% of ZBH outstanding, making it Wilsey’s 11th-largest holding.
• Zimmer Biomet beat quarterly expectations with EPS $2.42 (vs. $2.38 est.) and revenue of $2.24 billion (+10.9% YoY), and issued FY2026 guidance of 8.30–8.45 EPS (analysts’ consensus ~8.22).
• Institutional investors own 88.89% of the stock, analysts’ consensus rating is “Hold” with a $106.20 target, and the company announced a quarterly dividend of $0.24 (annualized $0.96, ~1.1% yield).

Wilsey Asset Management Inc. acquired a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 360,753 shares of the medical equipment provider's stock, valued at approximately $32,439,000. Zimmer Biomet makes up 5.0% of Wilsey Asset Management Inc.'s portfolio, making the stock its 11th biggest position. Wilsey Asset Management Inc. owned about 0.18% of Zimmer Biomet as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. Brighton Jones LLC purchased a new stake in shares of Zimmer Biomet during the 4th quarter valued at $204,000. Sivia Capital Partners LLC acquired a new position in Zimmer Biomet during the 2nd quarter valued at about $232,000. United Bank raised its stake in Zimmer Biomet by 10.7% in the second quarter. United Bank now owns 11,896 shares of the medical equipment provider's stock valued at $1,085,000 after buying an additional 1,153 shares during the last quarter. Creative Planning raised its stake in Zimmer Biomet by 24.1% in the second quarter. Creative Planning now owns 31,445 shares of the medical equipment provider's stock valued at $2,868,000 after buying an additional 6,105 shares during the last quarter. Finally, Nomura Asset Management Co. Ltd. boosted its holdings in Zimmer Biomet by 0.7% in the second quarter. Nomura Asset Management Co. Ltd. now owns 65,162 shares of the medical equipment provider's stock worth $5,943,000 after acquiring an additional 472 shares in the last quarter. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Stock Performance

Shares of NYSE ZBH opened at $88.04 on Friday. The stock has a market cap of $17.23 billion, a price-to-earnings ratio of 24.87, a PEG ratio of 1.83 and a beta of 0.58. Zimmer Biomet Holdings, Inc. has a 12 month low of $84.59 and a 12 month high of $114.44. The company has a 50 day simple moving average of $92.12 and a two-hundred day simple moving average of $94.73. The company has a current ratio of 1.98, a quick ratio of 1.10 and a debt-to-equity ratio of 0.55.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.38 by $0.04. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The firm had revenue of $2.24 billion during the quarter, compared to analysts' expectations of $2.22 billion. During the same quarter last year, the company posted $2.31 earnings per share. The firm's revenue was up 10.9% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. As a group, analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be paid a $0.24 dividend. The ex-dividend date is Tuesday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.1%. Zimmer Biomet's dividend payout ratio is presently 27.12%.

Insider Buying and Selling

In related news, SVP Lori Winkler sold 2,650 shares of the firm's stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $94.66, for a total transaction of $250,849.00. Following the sale, the senior vice president directly owned 10,224 shares of the company's stock, valued at $967,803.84. This trade represents a 20.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.39% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on ZBH shares. UBS Group reaffirmed a "sell" rating and issued a $89.00 price objective on shares of Zimmer Biomet in a research report on Wednesday, February 11th. William Blair began coverage on shares of Zimmer Biomet in a research note on Friday, February 20th. They set a "market perform" rating on the stock. The Goldman Sachs Group cut shares of Zimmer Biomet from a "neutral" rating to a "sell" rating and set a $93.00 price target for the company. in a report on Friday, January 9th. BTIG Research reissued a "buy" rating and set a $112.00 price objective on shares of Zimmer Biomet in a report on Tuesday, February 10th. Finally, Wells Fargo & Company raised their target price on Zimmer Biomet from $93.00 to $98.00 and gave the stock an "equal weight" rating in a research note on Wednesday, February 11th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, ten have issued a Hold rating and three have issued a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $106.20.

Zimmer Biomet Profile

Zimmer Biomet NYSE: ZBH is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company's product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.